Search Results - "van Steeg, Tamara J"

Toward the prediction of CNS drug-effect profiles in physiological and pathological conditions using microdialysis and mechanism-based pharmacokinetic-pharmacodynamic modeling by de Lange, Elizabeth C M, Ravenstijn, Paulien G M, Groenendaal, Dorien, van Steeg, Tamara J

“…Our ultimate goal is to develop mechanism-based pharmacokinetic (PK)-pharmacodynamic (PD) models to characterize and to predict CNS drug responses in both…”
Get full text

A model-based approach using GSK3772847, an anti-interleukin-33 receptor monoclonal antibody, as a showcase to predict SC administration PK and free target dynamics based on PK and total target measurements after IV administration by Berkhout, Jan, Fairman, Dave, van Noort, Martijn, van Steeg, Tamara J

“…Integrated modeling of the pharmacokinetic (PK) and target binding, by means of a TMDD model, can provide valuable insights into the expected pharmacodynamic…”
Get full text

Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach by Betts, Alison, Keunecke, Anne, van Steeg, Tamara J, van der Graaf, Piet H, Avery, Lindsay B, Jones, Hannah, Berkhout, Jan

“…The linear pharmacokinetics (PK) of therapeutic monoclonal antibodies (mAbs) can be considered a class property with values that are similar to endogenous IgG…”
Get full text

Pharmacokinetic-Pharmacodynamic Modeling of Alpha Interferon Response Induced by a Toll-Like 7 Receptor Agonist in Mice by BENSON, Neil, DE JONGH, Joost, DUCKWORTH, Jonathan D, JONES, Hannah M, PERTINEZ, Henry E, RAWAL, Jaiessh K, VAN STEEG, Tamara J, VAN DER GRAAF, Piet H

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Tumor necrosis factor-mediated disposition of infliximab in ulcerative colitis patients by Berends, Sophie E., van Steeg, Tamara J., Ahsman, Maurice J., Singh, Sharat, Brandse, Johannan F., D’Haens, Geert R. A. M., Mathôt, Ron A. A.

“…Ulcerative Colitis (UC) is an inflammatory bowel disease typically affecting the colon. Patients with active UC have elevated tumor necrosis factor (TNF)…”
Get full text

Systems Pharmacology Analysis of the Amyloid Cascade after β-Secretase Inhibition Enables the Identification of an Aβ42 Oligomer Pool by van Maanen, Eline M T, van Steeg, Tamara J, Michener, Maria S, Savage, Mary J, Kennedy, Matthew E, Kleijn, Huub Jan, Stone, Julie A, Danhof, Meindert

“…The deposition of amyloid-β (Aβ) oligomers in brain parenchyma has been implicated in the pathophysiology of Alzheimer's disease. Here we present a systems…”
Get more information

The application of mathematical modelling to the design of bispecific monoclonal antibodies by van Steeg, Tamara J, Bergmann, Kirsten Riber, Dimasi, Nazzareno, Sachsenmeier, Kris F, Agoram, Balaji

“…Targeting multiple receptors with bispecific antibodies is a novel approach that may prevent the development of resistance to cancer treatments. Despite the…”
Get full text

Influence of body composition on disposition of the highly fat distributed compound as analysed by physiologically based pharmacokinetic (PBPK) modeling and simulation by Goto, Akihiko, Tagawa, Yoshihiko, Moriya, Yuu, Sato, Sho, Yamamoto, Masami, Wakabayashi, Takeshi, Tsukamoto, Tetsuya, DeJongh, Joost, Steeg, Tamara J., Moriwaki, Toshiya, Asahi, Satoru

“…A recent study suggested that the pharmacokinetics (PK) of highly fat distributed compounds can be affected by acute changes in the volume of adipose tissue…”
Get full text

Impact of acute fat mobilisation on the pharmacokinetics of the highly fat distributed compound TAK‐357, investigated by physiologically based pharmacokinetic (PBPK) modeling and simulation by Goto, Akihiko, Tagawa, Yoshihiko, Moriya, Yuu, Sato, Sho, Furukawa, Yoshiyuki, Wakabayashi, Takeshi, Tsukamoto, Tetsuya, DeJongh, Joost, Steeg, Tamara J., Moriwaki, Toshiya, Asahi, Satoru

“…In a dog toxicokinetic study, an unusual plasma concentration increase of the highly lipophilic compound TAK‐357 was observed 2 weeks after termination of a…”
Get full text

Reproducible and time-dependent modification of serum protein binding in Wistar Kyoto rats by van Steeg, Tamara J., Krekels, Elke H.J., Danhof, Meindert, de Lange, Elizabeth C.M.

“…The theoretical basis of the influence of (alterations in) plasma protein binding on pharmacokinetics (PK) is well-established. In contrast, the impact of…”
Get full text

RESILIENCE MECHANISM OF THE AMYLOID PRECURSOR PROTEIN (APP) PATHWAY REVEALED BY SYSTEMS PHARMACOLOGY MODELING FOLLOWING β- AND GAMMA-SECRETASE INHIBITION by van Maanen, Eline M.T., van Steeg, Tamara J., Kalinina, Juliya, Stone, Julie, Michener, Maria S., Savage, Mary J., Kennedy, Matthew, Danhof, Meindert

Get full text

SYSTEMS PHARMACOLOGY ANALYSIS OF THE Aβ OLIGOMER RESPONSE FOLLOWING BACE1 INHIBITION: EVIDENCE FOR SECOND-ORDER Aβ42 OLIGOMERIZATION by van Maanen, Eline M.T., van Steeg, Tamara J., Kalinina, Juliya, Stone, Julie, Michener, Maria S., Savage, Mary J., Kennedy, Matthew, Parker, Eric, Danhof, Meindert

Get full text

Mechanism-based pharmacodynamic modeling of S(-)-atenolol: estimation of in vivo affinity for the beta1-adrenoceptor with an agonist-antagonist interaction model by van Steeg, Tamara J, Freijer, Jan, Danhof, Meindert, de Lange, Elizabeth C M

“…The aim of this study was the development of an agonist-antagonist interaction model to estimate the in vivo affinity of S(-)-atenolol for the…”
Get more information

Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach by Betts, Alison, Keunecke, Anne, van Steeg, Tamara J., van der Graaf, Piet H., Avery, Lindsay B., Jones, Hannah, Berkhout, Jan

“…The linear pharmacokinetics (PK) of therapeutic monoclonal antibodies (mAbs) can be considered a class property with values that are similar to endogenous IgG…”
Get full text

The application of mathematical modelling to the design of bispecific monoclonal antibodies by van Steeg, Tamara J., Bergmann, Kirsten Riber, Dimasi, Nazzareno, Sachsenmeier, Kris F., Agoram, Balaji

“…Targeting multiple receptors with bispecific antibodies is a novel approach that may prevent the development of resistance to cancer treatments. Despite the…”
Get full text